

**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Applicant: VISWANATHAN *et al.* Confirmation No.: 8748  
Serial No.: 10/532,296 Examiner: Westerberg, Nissa M..  
Filing Date: 2/6/2006 Group Art Unit: 1618  
For: SUSTAINED RELEASE COMPOSITIONS CONTAINING ALFUZOSIN

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT MAILED**  
**APRIL 6, 2009**

In response to the Office Action dated April 6, 2009, Applicants' elect Group I (claims 1, 5-10 and 18), drawn to a sustained release oral matrix tablet comprising alfuzosin, and a combination of hydroxypropylmethyl cellulose (HPMC) and hydroxypropyl cellulose (HPC).


Applicants' election is made without traverse and they reserve their rights to request consideration for rejoinder of these inventions at the appropriate time. Applicants also reserve their rights to file further divisional applications directed toward all non-elected subject matter of instant application. The Examiner is therefore requested to examine the elected claims immediately.

Authorization is hereby given to charge any fees deemed to be due in connection with this Response to Deposit Account No. 50-0912.

Respectfully submitted,

VISWANATHAN et al.

By:

  
George E. Heibel, Ph.D.

Reg. No. 42,648

Date: May 6, 2009

Ranbaxy Inc.  
600 College Road East, Suite 2100  
Princeton, New Jersey 08540  
Tel: (609) 720-5334  
Fax: (609) 514-9779